<DOC>
	<DOCNO>NCT01718626</DOCNO>
	<brief_summary>Stage 1 : First line therapy Sequential therapy S1+Docetaxel follow S1 superior concomitant S1+Docetaxel safety clinical efficiency . Stage 2 : Second line therapy To explore feasibility single drug ( S1 ) maintenance treatment advance gastric cancer .</brief_summary>
	<brief_title>Study Comparing Sequential Therapy S1+Docetaxel Followed S1 Concomitant S1+Docetaxel Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed informed consent form Performance StatusEastern Cooperative Oncology Group ( ECOG ) 01 Histologically cytologically confirm gastric cancer Advanced recurrent , metastatic disease At least one measurable disease ( accord RECIST , Response Evaluation Criteria Solid Tumors ) Life expectancy least 3 month Target target lesion receive radiotherapy non target lesion radiation least 4 week Haematopoietic Hepatic status : Absolute neutrophil count &gt; 1.5x109/L , Platelet count &gt; 100 x 109/L , Hemoglobin least 9 g/dl , Bilirubin ≤ 1.5 x upper limit normal ( ULN ) , AST ALT ≤ 2.5 time ULN ( liver metastasis ) , ≤5 time ULN ( liver metastasis ) Cardiovascular : Baseline LVEF 50 % measure echocardiography Symptomatic brain metastasis Active uncontrolled infection Unresolved unstable , serious toxicity prior cancer treatment ( toxicity great grade 2 ; peripheral neuropathy grade 2 great Symptomatic brain metastasis Known history uncontrolled symptomatic angina , clinically significant arrhythmia , congestive heart failure , uncontrolled hypertension ( ≥ 180/110 ) , unstable diabetes mellitus , dyspnea rest , chronic therapy oxygen History malignancy Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>